CABEI approves US$400.0 million for the purchase of vaccine against COVID-19 to eight SICA countries
These funds will be available through a credit facility as part of CABEI’s COVID-19 Support Program.
Tegucigalpa August 31, 2020.- The Board of directors of the Central American Bank for Economic Integration (CABEI), approved US$400.0 million for the procurement and application of vaccines against COVID-19 to eight countries of the Central American Integration System (SICA) through a Credit Facility from the Emergency Support and Preparedness Program for COVID-19 and Economic Reactivation.
This was reported by CABEI’s Executive President, Dr. Dante Mossi, who stressed that this approval accompanies and allows the countries of the Central American region to access this medical supply when it is already available and implement immunization actions for its population.
Likewise, Dr. Mossi highlighted the recent news that both Mexico and Argentina, two extra-regional partners of CABEI, have signed alliances with the University of Oxford and the AstraZeneca laboratory, to mass-produce vaccines for the Latin American market, which will allow timely and efficient access for all countries of the Central American region.
The Facility’s objective is to provide immediate financial resources to the sovereign public sector of the countries of the Central American region for the procurement and application of vaccines that protect the population’s immune system against the SARS-CoV-2 virus that causes the COVID-19 disease. This Facility will allow each country to have an allocation of US$50 million.
The US$400 million are part of the Emergency Support and Preparedness Program for COVID-19 and Economic Reactivation, which is now US$ 2,360.1 million. The Program has accompanied the Bank’s member countries by providing Quick-disbursement financial resources to finance operations for the prevention, detection and treatment of COVID-19 and mitigation of its economic impact in the countries.